Recombinant Human Prokineticin receptor 2 (PROKR2)

What is Prokineticin Receptor 2 and what are its primary biological functions?

Prokineticin Receptor 2 (PROKR2) is a G-protein coupled receptor that binds both Prokineticin 1 (PROK1) and Prokineticin 2 (PROK2), with PROK2 showing slightly higher binding affinity. While initially named for its role in stimulating gastrointestinal motility, PROKR2 has since been identified as a critical regulator of olfactory bulb morphogenesis and sexual maturation in mammals .

PROKR2 exhibits distinct anatomical expression patterns that explain its diverse biological functions. It is abundantly expressed in the brain—particularly in the olfactory bulb, subventricular zone, preoptic area, paraventricular nucleus, arcuate nucleus, and median eminence—as well as in the testes. This expression pattern contrasts with PROKR1, which is predominantly expressed in peripheral tissues including spleen, prostate, pancreas, heart, and blood cells .

How does PROKR2 signaling function at the molecular level?

PROKR2 activates multiple G-protein pathways common to GPCRs, including:

• Gαi/o pathway: Activates the MAPK/ERK signaling cascade

• Gαq pathway: Triggers the IP3/Ca²⁺ release pathway

• Gαs pathway: Stimulates the cAMP signaling pathway

These diverse signaling capabilities allow PROKR2 to mediate various cellular responses depending on the tissue context and physiological conditions. The receptor's signaling can be functionally assessed through several methodologies:

• Egr1-luciferase assays that measure MAPK/ERK activation

• Western blot analysis of phosphorylated ERK levels

• Aequorin-based assays to measure calcium release through the Gαq pathway

What phenotypes are associated with PROKR2 mutations in humans?

PROKR2 mutations are primarily associated with reproductive and olfactory disorders, including:

• Kallmann Syndrome (KS): Characterized by hypogonadotropic hypogonadism and anosmia/hyposmia

• Normosmic Idiopathic Hypogonadotropic Hypogonadism (nIHH): Presenting with reproductive dysfunction without olfactory defects

• More recently, PROKR2 variants have been linked to other endocrine disorders, including isolated growth hormone deficiency and more severe conditions such as septo-optic dysplasia

The varying phenotypes highlight PROKR2's roles in both neurodevelopmental processes and neuroendocrine function. Notably, identical PROKR2 mutations can produce considerable variation in clinical expressivity and penetrance of both reproductive and olfactory phenotypes .

What insights have animal models provided about PROKR2 function?

Mouse knockout models have been instrumental in understanding PROKR2 function. Prokr2-null mice present with:

• Abnormal olfactory bulb formation

• Severe atrophy of the reproductive system in both sexes

• Absence of GnRH-expressing neurons in the hypothalamus

These phenotypes mirror key aspects of Kallmann Syndrome in humans, establishing Prokr2 knockout mice as a valuable model for studying the molecular basis of this condition. Interestingly, while homozygous knockout mice show clear phenotypes, heterozygous mice reportedly develop normally—a contrast to humans, where heterozygous mutations are commonly associated with disease .

What functional assays are recommended for evaluating PROKR2 variants?

When investigating novel or known PROKR2 variants, researchers should consider multiple complementary approaches to assess functional consequences:

• For MAPK/ERK pathway assessment:

  • Egr1-luciferase assay: Cells are transfected with wild-type or mutant PROKR2 expression plasmids, along with luciferase vectors containing binding sites for EGR1 (a downstream effector of p-ERK). After stimulation with varying PROK2 concentrations, dose-response curves are generated.

  • Western blot analysis: Directly measuring phosphorylated ERK protein levels following PROK2 stimulation .

• For IP3/Ca²⁺ release pathway (Gαq) assessment:

  • Aequorin-based assays: These rely on transfection methods and measure calcium release in response to receptor activation .

• For cAMP pathway (Gαs) assessment:

  • cAMP accumulation assays using either radioimmunoassay or ELISA-based detection methods.

Each variant should be evaluated as a percentage of activation compared to wild-type PROKR2, across multiple signaling pathways, as mutations may affect different pathways differentially.

How should researchers approach the challenge of oligogenic inheritance in PROKR2-related disorders?

The investigation of oligogenic inheritance in PROKR2-related disorders requires systematic methodological approaches:

• Comprehensive genetic screening: Beyond PROKR2, panels should include genes frequently found in oligogenic combinations with PROKR2, particularly FGFR1, CHD7, ANOS1, PROK2, GNRHR, and SEMA3A .

• Family studies: Detailed phenotyping of family members carrying the same PROKR2 variants can reveal patterns of variable expressivity and incomplete penetrance that suggest oligogenic inheritance.

• Functional validation of variant combinations: When multiple variants are identified, functional studies should assess potential synergistic or additive effects on signaling pathways.

• Genome-wide approaches: For subjects with heterozygous PROKR2 mutations, whole exome or genome sequencing can identify additional genetic factors that may contribute to the phenotype .

The first reported case of oligogenicity involved a patient with Kallmann Syndrome carrying mutations in both PROK2 (ligand) and PROKR2 (receptor), demonstrating how defects in the same pathway can compound to produce disease .

What explains the "heterozygosity puzzle" in PROKR2 mutations?

The "heterozygosity puzzle" refers to the observation that while heterozygous Prokr2 knockout mice develop normally, humans with heterozygous PROKR2 mutations frequently display clinical phenotypes. This discrepancy suggests more complex regulatory mechanisms in humans compared to mice.

Potential explanations researchers should consider when investigating this phenomenon include:

• Oligogenic inheritance: Heterozygous PROKR2 mutations may interact with variants in other genes related to GnRH neuronal development or function.

• Genetic background effects: Different genetic backgrounds may influence the penetrance and expressivity of PROKR2 mutations.

• Nonsense-mediated decay and compensation: For certain PROKR2 variants (especially nonsense mutations), genetic compensation through increased transcription of adapting genes like PROKR1 may occur. PROKR1 and PROKR2 share ligands and have high homology, making this compensation plausible .

• Developmental timing differences: Species-specific differences in the timing of GnRH neuronal development may influence the impact of heterozygous mutations.

How can researchers investigate the "dual defect" hypothesis in PROKR2-related disorders?

Some patients with PROKR2 mutations exhibit persistent oligospermia or azoospermia despite gonadotropin treatment, suggesting a dual defect affecting both hypothalamic GnRH production and primary gonadal function . To investigate this hypothesis:

• Expression analysis: Characterize PROKR2 expression patterns in human testicular tissue, particularly in spermatocytes, building on evidence that PROKR2 is expressed in primary spermatocytes.

• Human gonadal phenotyping: Detailed phenotyping of gonadal function in patients with PROKR2 mutations, including testicular biopsy when appropriate, to identify specific spermatogenic defects.

• Conditional knockout models: Develop gonad-specific Prokr2 knockout mice to isolate the gonadal effects from hypothalamic effects.

• Genome-wide association studies: Further explore the association between PROKR2 variants and male infertility, building on pilot data linking a tagging SNP near the PROK2 gene with oligospermia and azoospermia .

• In vitro spermatogenesis models: Use in vitro models of spermatogenesis to directly test the effects of PROKR2 mutations on specific stages of sperm development.

How do researchers interpret discordant effects of PROKR2 mutations on different signaling pathways?

PROKR2 mutations can affect multiple signaling pathways differentially, creating complex phenotypic consequences. When analyzing functional data showing discordant effects:

• Structural mapping: Map mutations onto the receptor structure to identify which functional domains are affected (ligand binding, G-protein coupling, internalization). Different domains may preferentially couple to specific signaling pathways.

• Biased signaling analysis: Quantitatively compare the degree of impairment across different pathways (MAPK/ERK, IP3/Ca²⁺, cAMP) to determine if mutations create biased signaling profiles.

• Physiological relevance assessment: Determine which signaling pathways are most critical in specific tissues relevant to the clinical phenotype.

• Experimental design considerations:

  • Use multiple cell types for functional assays

  • Test both short-term and long-term signaling effects

  • Assess receptor localization and trafficking in addition to signaling output

What are the current hypotheses explaining why PROKR2 is not expressed on GnRH neurons despite its critical role in GnRH neuronal development?

One of the puzzling observations in PROKR2 biology is that despite its essential role in GnRH neuronal development and function, the PROKR2 receptor is conspicuously absent on both developing and mature adult GnRH neurons . This suggests indirect mechanisms of action.

Current research hypotheses include:

• Intermediary pathway hypothesis: PROKR2 may regulate other neuronal populations or factors that directly influence GnRH neuronal migration and function.

• Developmental timing effects: PROKR2 might be transiently expressed during critical windows of GnRH neuronal development but downregulated in mature neurons.

• Non-cell-autonomous effects: PROKR2 signaling in the surrounding neural environment may establish guidance cues or permissive conditions for GnRH neuronal migration.

• Glial cell mediation: PROKR2 expression in glial cells might indirectly regulate GnRH neuronal function through glial-neuronal communication.

Research approaches to test these hypotheses include single-cell transcriptomics of the developing olfactory/hypothalamic region, conditional and cell-type-specific knockout models, and co-culture systems to identify intermediate signaling factors.

What are the most promising areas for future PROKR2 research?

Based on current knowledge gaps and emerging findings, future PROKR2 research should focus on:

• Systems biology approaches: Identifying interacting proteins, chaperones, transcription factors, and second messengers that mediate PROKR2 signaling .

• Non-reproductive functions: Investigating PROKR2's roles beyond reproduction, as suggested by additional non-reproductive phenotypes observed in some patients .

• Therapeutic targeting: Developing agonists or antagonists that can modulate specific PROKR2 signaling pathways for potential therapeutic applications in reproductive disorders.

• Structural biology: Determining the three-dimensional structure of PROKR2 to better understand ligand binding and receptor activation mechanisms.

• Precision medicine approaches: Developing personalized treatment strategies based on specific PROKR2 variants and their functional consequences.

The continued study of PROKR2 biology promises to advance our understanding of reproductive neuroendocrinology and may provide new therapeutic avenues for patients with reproductive and developmental disorders.